FILING ANALYSIS · THURSDAY, NOVEMBER 12
RELMADA THERAPEUTICS, INC. RLMD — 8-K: Results of Operations and Financial Condition
neutral
Relmada Therapeutics reported preliminary unaudited financial results for Q3 2026 and provided a business update, including 18-month results from the NDV-01 Phase 2 study showing extended durability of complete response and favorable tolerability, with cash and equivalents of $202.1 million expected to fund operations through 2029. No quantified surprises were disclosed in the filing.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →